Compare VRTX & MCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | MCK |
|---|---|---|
| Founded | 1989 | 1833 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Other Pharmaceuticals |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 101.9B |
| IPO Year | 2006 | 1995 |
| Metric | VRTX | MCK |
|---|---|---|
| Price | $455.90 | $916.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 13 |
| Target Price | $526.79 | ★ $930.23 |
| AVG Volume (30 Days) | ★ 1.3M | 747.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.35% |
| EPS Growth | ★ 836.54 | 14.87 |
| EPS | 15.32 | ★ 24.73 |
| Revenue | $2,488,652,000.00 | ★ $112,084,000,000.00 |
| Revenue This Year | $10.79 | $14.97 |
| Revenue Next Year | $10.14 | $8.20 |
| P/E Ratio | ★ $30.10 | $37.66 |
| Revenue Growth | ★ 46.20 | 3.11 |
| 52 Week Low | $362.50 | $633.53 |
| 52 Week High | $519.68 | $999.00 |
| Indicator | VRTX | MCK |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 47.01 |
| Support Level | $455.62 | $796.22 |
| Resistance Level | $465.98 | N/A |
| Average True Range (ATR) | 13.17 | 17.27 |
| MACD | -2.82 | -6.87 |
| Stochastic Oscillator | 13.47 | 8.67 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.